Education
About Us
Working with TipRanks
Follow Us
ProQR Therapeutics BV (PRQR)
:PRQR
PRQR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.07 - $4.62
Previous CloseN/A
Volume75.97K
Average Volume (3M)704.80K
Market Cap
$124.15M
Enterprise Value$66.50M
Total Cash (Recent Filing)€4.13M
Total Debt (Recent Filing)€3.54M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
May 08, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding105,212,524
10 Day Avg. Volume574,703
30 Day Avg. Volume704,801
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.70
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.80Price Target Upside723.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
ProQR News
PremiumCompany Announcements
ProQR Announces New CFO and CMO to Drive Growth
PremiumCompany Announcements
ProQR Therapeutics Advances RNA Editing Pipeline
PremiumCompany Announcements
ProQR Therapeutics Reports 2024 Results and Pipeline Progress
---
Bulls Say, Bears Say
Bulls Say
Financial HealthPRQR ended with $156M in cash, which management estimates is sufficient runway into mid-2027.
PartnershipsProQR continues to execute on its partnership with Lilly, which includes potential data updates and milestone income.
Technology And InnovationProQR with its Axiomer technology finds itself in a unique position to exploit the EON based therapeutic editing for targeting genetically validated diseases with huge unmet need.
Bears Say
Market ChallengesThe continued stock decline following a mid-October spike suggests recent market challenges for PRQR.
Pipeline RisksCatalysts are finally coming back after a multi-year pipeline reset post the LCA10 failure three years ago.
---
Ownership Overview
―
Insiders
2.60% Mutual Funds
32.46% Other Institutional Investors
64.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRQR FAQ
What was ProQR Therapeutics BV’s price range in the past 12 months?
ProQR Therapeutics BV lowest stock price was $1.07 and its highest was $4.62 in the past 12 months.
What is ProQR Therapeutics BV’s market cap?
ProQR Therapeutics BV’s market cap is $124.15M.
When is ProQR Therapeutics BV’s upcoming earnings report date?
ProQR Therapeutics BV’s upcoming earnings report date is May 08, 2025 which is in 22 days.
How were ProQR Therapeutics BV’s earnings last quarter?
ProQR Therapeutics BV released its earnings results on Mar 13, 2025. The company reported -$0.102 earnings per share for the quarter, beating the consensus estimate of -$0.105 by $0.003.
Is ProQR Therapeutics BV overvalued?
According to Wall Street analysts ProQR Therapeutics BV’s price is currently Undervalued.
Does ProQR Therapeutics BV pay dividends?
ProQR Therapeutics BV does not currently pay dividends.
What is ProQR Therapeutics BV’s EPS estimate?
ProQR Therapeutics BV’s EPS estimate is -0.11.
How many shares outstanding does ProQR Therapeutics BV have?
ProQR Therapeutics BV has 105,212,524 shares outstanding.
What happened to ProQR Therapeutics BV’s price movement after its last earnings report?
ProQR Therapeutics BV reported an EPS of -$0.102 in its last earnings report, beating expectations of -$0.105. Following the earnings report the stock price went down -5.946%.
Which hedge fund is a major shareholder of ProQR Therapeutics BV?
Currently, no hedge funds are holding shares in PRQR
---
ProQR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.80 (723.53% Upside)
$9.80 (723.53% Upside)
Hedge Fund Trend
Increased
By 5.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.80%
12-Months-Change
Fundamentals
Return on Equity
-43.72%
Trailing 12-Months
Asset Growth
14.19%
Trailing 12-Months
Company Description
ProQR Therapeutics BV
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
---
PRQR Stock 12 Month Forecast
Average Price Target
$9.80
▲(723.53% Upside)
Technical Analysis
Best Analysts Covering PRQR
1 Year
1 Year Success Rate
11/26 ratings generated profit
1 Year Average Return
-17.04%
reiterated a buy rating last month
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 42.31% of your transactions generating a profit, with an average return of -17.04% per trade.
---